Cargando…

JAK2-negative acute monocytic leukemia with TET2 mutation in essential thrombocythemia with JAK2 mutation with literature review

Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm (MPN) with a transformation to acute myeloid leukemia in <5% of patients. A 79-year-old man with JAK2V617F-positive ET exhibited leukocytosis with an increase in monoblastic cells, leading to a diagnosis of acute monoblasti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogasawara, Toshie, Kawauchi, Kiyotaka, Ono, Takuya, Marshall, Shoko, Shide, Kotaro, Shimoda, Kazuya, Mori, Naoki, Sakura, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997900/ https://www.ncbi.nlm.nih.gov/pubmed/32042586 http://dx.doi.org/10.1016/j.lrr.2019.100194

Ejemplares similares

Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
por: Kubuki, Yoko, et al.
Publicado: (2017)

JAK2 and TET2 Mutation in Polycythemia Vera
por: Padda, Jaskamal, et al.
Publicado: (2021)

Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia
por: Kang, Min-Gu, et al.
Publicado: (2016)

Mutant calreticulin causes essential thrombocythemia
por: Shimoda, Kazuya, et al.
Publicado: (2017)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Selected Parameters of Angiogenesis and the JAK2, CALR, and MPL Mutations in Patients With Essential Thrombocythemia
por: Gadomska, Grażyna, et al.
Publicado: (2018)

A Rare Case of Essential Thrombocythemia with Coexisting JAK2 and MPL Driver Mutations
por: Jang, Mi-Ae, et al.
Publicado: (2020)

Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib
por: Shide, K, et al.
Publicado: (2017)

Oral squamous cell carcinoma with essential thrombocythemia and positive JAK2 (V617F) mutation
por: Rahman, Kurnia H., et al.
Publicado: (2021)

Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia
por: Abdelghani, Maroua, et al.
Publicado: (2022)

Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms
por: Kameda, Takuro, et al.
Publicado: (2015)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
por: Yönal, İpek, et al.
Publicado: (2016)

Familial Essential Thrombocythemia Associated with MPL W515L Mutation in Father and JAK2 V617F Mutation in Daughter
por: Trifa, Adrian P., et al.
Publicado: (2014)

Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia
por: Lim, Ken-Hong, et al.
Publicado: (2017)

Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemia
por: Ji, Liying, et al.
Publicado: (2017)

Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia
por: Vu, Hoang Anh, et al.
Publicado: (2019)

A case of ischemic stroke with hemorrhagic transformation associated with essential thrombocythemia and JAK-2 V617F mutation
por: Yan, Ran, et al.
Publicado: (2022)

PB2250: THE IMPACT OF JAK2V617F MUTATION POSITIVITY IN ESSENTIAL THROMBOCYTHEMIA:ABOUT 74 CASES.
por: Cheffai, Arij, et al.
Publicado: (2023)

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
por: Passamonti, Francesco, et al.
Publicado: (2011)

A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
por: Verstovsek, Srdan, et al.
Publicado: (2017)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Simultaneous presentation of JAK2 V617F mutation-related essential thrombocythemia and B-cell chronic lymphocytic leukemia
por: D'Angelo, Guido, et al.
Publicado: (2014)

Jak-2 mutation frequency in patients with thrombocytosis
por: Yokus, Osman, et al.
Publicado: (2018)

Chronic urticaria reveals JAK2V617F positive essential thrombocythemia
por: Albanesi, Marcello, et al.
Publicado: (2021)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study
por: Cascavilla, Nicola, et al.
Publicado: (2015)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis
por: Lim, K-H, et al.
Publicado: (2015)

Essential Thrombocythemia and Ischemic Stroke: A Case Series of Five JAK2-Positive Patients
por: Kim, Byong-Kyu, et al.
Publicado: (2023)

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2(V617F) mutation
por: Fan, Wenjuan, et al.
Publicado: (2023)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

Acquired JAK2 mutations confer resistance to JAK inhibitors in cell models of acute lymphoblastic leukemia
por: Downes, Charlotte E. J., et al.
Publicado: (2021)

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
por: Tefferi, A
Publicado: (2010)

Curcumin induces apoptosis in JAK2‐mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways
por: Petiti, Jessica, et al.
Publicado: (2019)

Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils
por: Kimishima, Yusuke, et al.
Publicado: (2021)

Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy
por: Treliński, Jacek, et al.
Publicado: (2012)

Case report: Double L611S/V617L JAK2 mutation in a patient with polycythemia vera originally diagnosed with essential thrombocythemia
por: Li, Xiao-qing, et al.
Publicado: (2022)

Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
por: Eickhardt-Dalbøge, Christina Schjellerup, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cn1i9fhpql6e4haopomrlpvvv2